| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial.
|
Blood
|
2004
|
1.78
|
|
2
|
Breast cancer resistance protein and P-glycoprotein in 149 adult acute myeloid leukemias.
|
Clin Cancer Res
|
2004
|
1.41
|
|
3
|
Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10.
|
J Clin Oncol
|
2009
|
1.41
|
|
4
|
Plasmacytoid dendritic cells accumulate in spleens from chronically HIV-infected patients but barely participate in interferon-alpha expression.
|
Blood
|
2009
|
1.24
|
|
5
|
Semisynthetic homoharringtonine induces apoptosis via inhibition of protein synthesis and triggers rapid myeloid cell leukemia-1 down-regulation in myeloid leukemia cells.
|
Mol Cancer Ther
|
2006
|
1.22
|
|
6
|
Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study.
|
Blood
|
2005
|
1.18
|
|
7
|
Oncologic trogocytosis of an original stromal cells induces chemoresistance of ovarian tumours.
|
PLoS One
|
2008
|
1.17
|
|
8
|
MRP3, BCRP, and P-glycoprotein activities are prognostic factors in adult acute myeloid leukemia.
|
Clin Cancer Res
|
2005
|
1.15
|
|
9
|
High Id1 expression is associated with poor prognosis in 237 patients with acute myeloid leukemia.
|
Blood
|
2009
|
1.11
|
|
10
|
High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial.
|
J Clin Oncol
|
2013
|
1.07
|
|
11
|
Value of allogeneic versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. Final results of a prospective randomized European Intergroup Trial.
|
Haematologica
|
2010
|
1.05
|
|
12
|
Prospective evaluation of a polymerase chain reaction-ELISA targeted to Aspergillus fumigatus and Aspergillus flavus for the early diagnosis of invasive aspergillosis in patients with hematological malignancies.
|
J Infect Dis
|
2006
|
1.04
|
|
13
|
Prognosis of patients with acute myeloid leukaemia admitted to intensive care.
|
Br J Haematol
|
2005
|
1.00
|
|
14
|
Evaluation and comparison of MRP1 activity with three fluorescent dyes and three modulators in leukemic cell lines.
|
Leuk Res
|
2004
|
1.00
|
|
15
|
Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia.
|
Invest New Drugs
|
2011
|
0.99
|
|
16
|
Sequential combination of gemtuzumab ozogamicin and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia: results of a randomized phase III trial by the EORTC and GIMEMA consortium (AML-17).
|
J Clin Oncol
|
2013
|
0.96
|
|
17
|
JC-1, a sensitive probe for a simultaneous detection of P-glycoprotein activity and apoptosis in leukemic cells.
|
Cytometry B Clin Cytom
|
2006
|
0.93
|
|
18
|
ATP Binding Cassette transporters associated with chemoresistance: transcriptional profiling in extreme cohorts and their prognostic impact in a cohort of 281 acute myeloid leukemia patients.
|
Haematologica
|
2011
|
0.88
|
|
19
|
Bacteremia caused by an undescribed species of Janibacter.
|
J Clin Microbiol
|
2005
|
0.87
|
|
20
|
Outcome of 40 adults aged from 18 to 55 years with acute lymphoblastic leukemia treated with double-delayed intensification pediatric protocol.
|
Leuk Res
|
2011
|
0.87
|
|
21
|
P-gp activity is a critical resistance factor against AVE9633 and DM4 cytotoxicity in leukaemia cell lines, but not a major mechanism of chemoresistance in cells from acute myeloid leukaemia patients.
|
BMC Cancer
|
2009
|
0.86
|
|
22
|
Zosuquidar restores drug sensitivity in P-glycoprotein expressing acute myeloid leukemia (AML).
|
BMC Cancer
|
2008
|
0.85
|
|
23
|
Soluble endothelial protein C receptor (sEPCR) is likely a biomarker of cancer-associated hypercoagulability in human hematologic malignancies.
|
Cancer Med
|
2012
|
0.84
|
|
24
|
Applying ecological and evolutionary theory to cancer: a long and winding road.
|
Evol Appl
|
2012
|
0.84
|
|
25
|
Liposomal nystatin in patients with invasive aspergillosis refractory to or intolerant of amphotericin B.
|
Antimicrob Agents Chemother
|
2004
|
0.83
|
|
26
|
Flt3 internal tandem duplication and P-glycoprotein functionality in 171 patients with acute myeloid leukemia.
|
Clin Cancer Res
|
2006
|
0.82
|
|
27
|
Clinical and biological impact of TET2 mutations and expression in younger adult AML patients treated within the EORTC/GIMEMA AML-12 clinical trial.
|
Ann Hematol
|
2014
|
0.81
|
|
28
|
The detection of CD14 and CD16 in paraffin-embedded bone marrow biopsies is useful for the diagnosis of chronic myelomonocytic leukemia.
|
Virchows Arch
|
2009
|
0.81
|
|
29
|
Dexamethasone compared to prednisolone for adults with acute lymphoblastic leukemia or lymphoblastic lymphoma: final results of the ALL-4 randomized, phase III trial of the EORTC Leukemia Group.
|
Haematologica
|
2010
|
0.81
|
|
30
|
Intensive consolidation therapy compared with standard consolidation and maintenance therapy for adults with acute myeloid leukaemia aged between 46 and 60 years: final results of the randomized phase III study (AML 8B) of the European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups.
|
Ann Hematol
|
2012
|
0.81
|
|
31
|
Reticulated platelets: a reliable measure to reduce prophylactic platelet transfusions after intensive chemotherapy.
|
Transfusion
|
2005
|
0.78
|
|
32
|
Usefulness of PKH fluorescent labelling to study leukemic cell proliferation with various cytostatic drugs or acetyl tetrapeptide--AcSDKP.
|
BMC Cancer
|
2005
|
0.77
|
|
33
|
Specific scoring systems to predict survival of patients with high-risk myelodysplastic syndrome (MDS) and de novo acute myeloid leukemia (AML) after intensive antileukemic treatment based on results of the EORTC-GIMEMA AML-10 and intergroup CRIANT studies.
|
Ann Hematol
|
2014
|
0.77
|
|
34
|
P-glycoprotein and multidrug resistance associated protein-1 activity in 132 acute myeloid leukemias according to FAB subtypes and cytogenetics risk groups.
|
Haematologica
|
2004
|
0.75
|
|
35
|
Lethal pulmonary hemorrhage caused by a fulminant Stenotrophomonas maltophilia respiratory infection in an acute myeloid leukemia patient.
|
Leuk Lymphoma
|
2004
|
0.75
|
|
36
|
Incidence rates of leukemia in French Polynesia.
|
Int J Cancer
|
2012
|
0.75
|
|
37
|
Endothelial cell markers' kinetics following umbilical cord blood transplantation.
|
Leuk Lymphoma
|
2008
|
0.75
|
|
38
|
Intravesical Bacillus Calmette-Guerin for the treatment of superficial bladder cancer following hematopoietic stem cell transplantation.
|
Leuk Lymphoma
|
2008
|
0.75
|
|
39
|
[Update on malignant hemopathies].
|
Bull Cancer
|
2002
|
0.75
|
|
40
|
A new acute lymphoblastic leukaemia cell line BEL-1 with t(4; 11) (q21; q23) chromosomal translocation and a unique aberrant p27 transcript.
|
Br J Haematol
|
2004
|
0.75
|
|
41
|
The BH3-only protein Noxa is stimulated during apoptosis of chronic lymphocytic leukemia cells triggered by M2YN, a new plant-derived extract.
|
Int J Oncol
|
2011
|
0.75
|
|
42
|
Comparison of flow cytometry and enzyme cytochemistry for the detection of myeloperoxydase in acute myeloid leukaemia: interests of a new positivity threshold.
|
Br J Haematol
|
2003
|
0.75
|
|
43
|
Major improvement of the reference method of the French drug resistance network for P-glycoprotein detection in human haematological malignancies.
|
Leuk Res
|
2005
|
0.75
|
|
44
|
Double-delayed intensification paediatric protocol without radiotherapy is an efficient treatment in adult lymphoblastic lymphoma.
|
Hematol Oncol
|
2012
|
0.75
|
|
45
|
Acute myeloid leukemia in the elderly: etoposide when anthracyclins are contraindicated.
|
Leuk Lymphoma
|
2005
|
0.75
|
|
46
|
Long-term imatinib maintenance therapy for adult Philadelphia positive acute lymphoblastic leukemia.
|
Leuk Lymphoma
|
2014
|
0.75
|